November 3, 2020 07:36 AM ESTUpdated 11:10 AM
R&D

Jounce shares take a beat­ing as their lead drug spurs on­ly a weak re­sponse in PhII — tri­al halt­ed

Max Gelman

Senior Editor

A lit­tle over two months af­ter Jounce Ther­a­peu­tics $JNCE sold its lat­est ex­per­i­men­tal can­cer drug to Gilead, the com­pa­ny’s lead pro­gram has failed to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

A service from the Financial Times